HUTCHMED Reports Enrollment Completion in P-II Trial of Savolitinib for Gastric Cancer in China
Shots:
- HUTCHMED has completed pts enrollment in P-II trial assessing savolitinib for G/GEJ adenocarcinoma pts (n=64) with MET amplification to evaluate ORR per IRC (1EP) & 2EPs incl. PFS & AE incidence; HUTCHMED plans to file for potential NMPA’s Approval in late 2025
- Interim analysis of the trial showed 45% cORR by IRC & 50% ORR in pts with high MET gene copy number; 4mos. DoR rate was 85.7%, with a mFU of 5.5mos. Data was presented at AACR 2023
- Savolitinib is a MET tyrosine kinase inhibitor co-developed by AstraZeneca and HUTCHMED and is being commercialized by AstraZeneca
Ref: HUTCHMED | Image: HUTCHMED
Related News:- HUTCHMED Receives NMPA’s Conditional Approval for Tazverik to Treat R/R Follicular Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
